Comparative Analysis of the Pharmacological Activity of Bis(3,5-di-Tert-Butyl-4-Hydroxyphenylthiolate)Dimethylol in Different Modes of Administration on a Mouse Model of Melanoma B16 Tumor Growth

Bulletin of Experimental Biology and Medicine - We performed a comparative analysis of the pharmacological activity of the hybrid organotin compound...     

Comparative study of the effect of drug therapy and its combination with hyperbaric oxygenation and hemosorption on stable angina pectoris]

Seventy seven males aged under 60 years with Functional Classes II-IV stable angina were examined. The patients were randomly divided into 3 groups: 1) 24 patients receiving drug therapy alone; 2) 27 patients taking drug therapy in combination with hyperbaric oxygenation; and 3) 26 patients having drug therapy in combination with hemosorption. In all the patient groups, there was a reduction in the frequency of resting and exercise anginal attacks, in Group 3, exercise tolerance was increased due to drug therapy. In a re-examination, there was a significant fall in total cholesterol and high-density lipoprotein cholesterol levels only in Group 3. A comparison of daily drug doses indicated that the functional class improved only due to the adequate antianginal therapy. Thus, hyperbaric oxygenation and hemosorption have no significant action on the degree of stable angina.     

Safety and Effectiveness of Essential Phospholipids Paste in Patients with Non-alcoholic Fatty Liver Disease or Viral Hepatitis

Background: Essential phospholipids (EPL) are used as adjuvant treatment in people with fatty liver disease and other chronic liver diseases. A new formulation of EPL paste was developed to improve patient compliance. The study was aimed to assess the safety, patient-reported outcomes, and impact on compliance of the new EPL paste formulation in patients with non-alcoholic fatty liver disease (NAFLD) or viral hepatitis.Methods: The study enrolled 147 patients (48.3% male; mean ± standard deviation (SD) age 44.8 ± 10.5 years) in the intention-to-treat population; 72.8% had NAFLD and 27.9% had viral hepatitis B (HBV) or hepatitis C (HCV). Patients received EPL paste (one 600 mg sachet 3 times daily) for 12 weeks, with 4-, 8-, and 12-week scheduled visits and a 13-week follow-up visit. Patient-reported outcomes were evaluated at 4, 8, and 12 weeks compared with baseline using dedicated Likert scales. Compliance was assessed by comparing actual versus prescribed dosing of the EPL.Results: After 12-week treatment with EPL paste, statistically significant improvements were observed in mean ± SD Global Overall Symptom scores (from 4.21 ± 1.09 to 1.87 ± 0.91; P < .01) and overall Gastrointestinal Symptom scores (from 19.91 ± 5.74 to 11.17 ± 3.57; P < .01), compared to baseline scores. Compliance with prescribed essential phospholipid treatment was 99% throughout the 12-week treatment period.Conclusion: Essential phospholipids paste had a favorable safety profile associated with improved gastrointestinal symptoms and with high levels of compliance in patients with NAFLD and viral hepatitis.